POS-690 Outcomes of Malignancy in Kidney Transplant Recipients

Malignancy, cardiovascular events, and infections are the leading causes of death among kidney transplant (KT) recipients. The risk cancer in KT recipient is two to 4 folds increased than general population with reported higher mortality rates. Post-transplant malignancies can be related de novo development, donor-related transmission, recurrence a recipient’s pre-transplant malignancy. Common post transplantation non-melanotic skin cancer, Kaposi sarcoma, post-transplant lym­phoproliferative disorder (PTLD), renal cell carcinoma (RCC), anogenital cancer. We aim study types outcomes tertiary oncology center United Arab Emirate. A retrospective chart review was conducted at Tawam Hospital from January 2009 July 2020 after ethical approval. included adult recipients (age > 16) who were diagnosed transplantation. Demographic, laboratory data clinical analyzed using descriptive analysis. total 528 identified during period, 26 patients (4.9%) fulfilled inclusion criteria. mean age 54.57 years, female male ratio 1:1, 14 (53.8%) national. All received living donors (related 7, unrelated 19), had second transplant, one liver transplant. maintenance immunosuppressive (IS) medications prior diagnosis Tacrolimus (10), cyclosporine (13), prednisolone (23), mycophenolate mofetil (14), mycophenolic acid (4), azathioprine (3) sirolimus (1). comorbid conditions our cohort hypertension (23 [88.4%]), diabetes mellitus (15 [57.6%]), ischemic heart disease (4 [15.3%]), dyslipidemia (19 [73%]), history rejection (10 [38.4%]) hepatitis C or B virus (4[15.3%]). duration between 9.1 years. Hematological seen 27 % (n=7), while rest (73 %) non hematological (n=19). most common malignancy PTLD (n=6) patient acute myeloid leukemia (AML). median interval ranged 3 Four required chemotherapy along reduction IS AML underwent allogeneic bone marrow (Allo-HSCT). non-hematological gastrointestinal (n=5 [19%]), breast (Infiltrating ductal carcinoma) (n=4 [15%]), (n= [11.5%]), (n=2), papillary thyroid sarcoma (1), giant tumor (n=1) cervical (n=1). Half metastatic (53.8%). management adjustment medications, for 16 [61.5%]), surgery (14 [53.8%]) radiotherapy [38.4%]). Palliative care provided five patients. Mortality rate high 42% (cancer related, cardiac event, septic shock). incidence over 10 years 4.9 predominance late onset mainly lymphoma. Larger studies needed elucidate potential factors understand geographical difference cancers such